NCT05866679SuspendedPhase 1
Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Reason given: Suspension
Brief summary (registry, in English)
To learn if an MRSI can be performed on a 3T scanner using an investigational contrast drug called hyperpolarized 13-C pyruvate. 3T refers to the "strength" of the MRI machine.
- Status (registry)
- Suspended
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 10 May 2023
- Start date
- 12 Apr 2024
- Primary completion date
- 31 Aug 2028
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Childhood cancers, Ovarian cancer
- NCT number
- NCT05866679
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- (all cohorts)
- Children, pregnant women, cognitively impaired adults, or prisoners will be excluded from participation.
Who the study is looking for
- For the first cohort, the following selection criteria will be applied who are undergoing a screening exam at MD Anderson:
- Patients with a first degree relative (mother, sister, or daughter) with ovarian cancer or
- A personal history of breast cancer before age 40 or
- A personal history of breast cancer diagnosed before age 50, and one or more close relatives diagnosed with breast or ovarian cancer at any age. Two or more close relatives diagnosed with breast cancer before age 50 or with ovarian cancer diagnosed at any age or
- Ashkenazi Jewish heritage and a personal history of breast cancer before age 50 or
- Ashkenazi Jewish heritage and a first- or second-degree relative diagnosed with breast cancer before age 50 or with ovarian cancer at any age or
- Presence of a BRCA1 or BRCA2 mutation or
- Presence of a mismatch repair gene mutation associated with a hereditary cancer syndrome known as Hereditary Non-Polyposis Colon Cancer (HNPCC)/Lynch syndrome. For the second cohort- 10 Patients will be enrolled who present to MD Anderson for a pelvic ultrasound or have an outside ultrasound or imaging study without a mass or have an adnexal mass (benign) on outside imaging and do not have a high risk for ovarian cancer.
- For the third cohort of patients:
- 10 patients who have suspicion of ovarian malignancy on conventional imaging and will be undergoing surgical resection will be included.
Age in the registry: 18 months to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.